发布求助
文献互助 智能选刊 最新文献

Im Fokus Onkologie最新文献

筛选
英文 中文
HCC: Durvalumab als Monotherapie zugelassen HCC：Durvalumab获批作为单药治疗
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3800-y
Andrea Warpakowski
{"title":"HCC: Durvalumab als Monotherapie zugelassen","authors":"Andrea Warpakowski","doi":"10.1007/s15015-024-3800-y","DOIUrl":"https://doi.org/10.1007/s15015-024-3800-y","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":"101 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140794825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rezidivierendes Ovarialkarzinom: Benefit mit Maveropepimut-S Rezidivierendes Ovarialkarzinom：使用罂粟碱的益处
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3789-2
B. Fessler
{"title":"Rezidivierendes Ovarialkarzinom: Benefit mit Maveropepimut-S","authors":"B. Fessler","doi":"10.1007/s15015-024-3789-2","DOIUrl":"https://doi.org/10.1007/s15015-024-3789-2","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":"66 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140795202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AML und MDS: Was tun bei Rezidiv nach HSZT? 急性髓细胞白血病和骨髓增生异常综合征：造血干细胞移植后复发怎么办？
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3770-0
Marie-Thérèse Weitzl
{"title":"AML und MDS: Was tun bei Rezidiv nach HSZT?","authors":"Marie-Thérèse Weitzl","doi":"10.1007/s15015-024-3770-0","DOIUrl":"https://doi.org/10.1007/s15015-024-3770-0","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":"8 3","pages":"61"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140785212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
cGvHD: Neue Hoffnung durch Anti-CSF-1R-Antikörper cGvHD：抗CSF-1R抗体带来新希望
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-024-3751-3
F. Klein
{"title":"cGvHD: Neue Hoffnung durch Anti-CSF-1R-Antikörper","authors":"F. Klein","doi":"10.1007/s15015-024-3751-3","DOIUrl":"https://doi.org/10.1007/s15015-024-3751-3","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":"25 3","pages":"60"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139684243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urothelkarzinom: kaum Überlebensvorteil mit PD-L1-Hemmer 尿路上皮癌：PD-L1抑制剂几乎无法改善生存状况
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-024-3727-3
T. Müller
{"title":"Urothelkarzinom: kaum Überlebensvorteil mit PD-L1-Hemmer","authors":"T. Müller","doi":"10.1007/s15015-024-3727-3","DOIUrl":"https://doi.org/10.1007/s15015-024-3727-3","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":"46 18","pages":"53"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139685992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
r/r DLBCL: Polatuzumab-Vedotin ist eine reale Option r/r DLBCL：Polatuzumab vedotin是一个真正的选择
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-023-3713-1
Christian Behrend
{"title":"r/r DLBCL: Polatuzumab-Vedotin ist eine reale Option","authors":"Christian Behrend","doi":"10.1007/s15015-023-3713-1","DOIUrl":"https://doi.org/10.1007/s15015-023-3713-1","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":"58 1","pages":"58"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139687275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Studienteilnehmende gesucht! 研究人员希望
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-024-3726-4
Redaktion Facharztmagazine
{"title":"Studienteilnehmende gesucht!","authors":"Redaktion Facharztmagazine","doi":"10.1007/s15015-024-3726-4","DOIUrl":"https://doi.org/10.1007/s15015-024-3726-4","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":"52 8","pages":"52"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139687554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends bei der Existenzgründung 创业趋势
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-024-3736-2
Hauke Gerlof
{"title":"Trends bei der Existenzgründung","authors":"Hauke Gerlof","doi":"10.1007/s15015-024-3736-2","DOIUrl":"https://doi.org/10.1007/s15015-024-3736-2","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":"69 3","pages":"65"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139965930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Betriebliche Gesundheitsförderung 促进工作场所健康
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-023-3715-z
F. Klein
{"title":"Betriebliche Gesundheitsförderung","authors":"F. Klein","doi":"10.1007/s15015-023-3715-z","DOIUrl":"https://doi.org/10.1007/s15015-023-3715-z","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":"56 11","pages":"46-51"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139687801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemtherapie beim fortgeschrittenen Leberzellkarzinom 晚期肝细胞癌的全身治疗
Im Fokus Onkologie Pub Date : 2024-02-01 DOI: 10.1007/s15015-024-3734-4
Pamela Proissl, G. Hausner, H. Wege
{"title":"Systemtherapie beim fortgeschrittenen Leberzellkarzinom","authors":"Pamela Proissl, G. Hausner, H. Wege","doi":"10.1007/s15015-024-3734-4","DOIUrl":"https://doi.org/10.1007/s15015-024-3734-4","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":"97 5","pages":"15-18"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139684789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信